Search PubMed⌕ Search

Biomedical subjects

A Roth

Publications and source records attributed to A Roth.

At least 361 records · Page 20Linked to original sources
PubMed1980

Bleomycin infusions combined with radiotherapy in the treatment of inoperable esophageal cancer.

A combination of bleomycin, in a 12 h infusion, and radiotherapy was applied in 25 patients with untreated inoperable esophageal cancer. Bleomycin was administered 15 mg/m2 twice weekly, concurrently with irradiation (total dose 3600-4000 rad). Such combined treatment produced 3 complete remissions of the esophageal tumor, 10 partial remissions (response rate 52%--13/25), 3 stable disease cases, while in 9 cases the disease progressed in spite of therapy. The median duration of remissions was 8.7 months in complete responders, 6.0 months in partial responders, and 3.0 months in stable disease cases. Similarly, median survival was the longest in complete remission cases (10.3 months). Patients who did not respond to therapy had a median survival of only 2.8 months. Adverse treatment reactions were of a milder character, except retrosternal pain and burning caused by irradiation mucositis, which occurred in 80% of patients. The trial showed that the combination of bleomycin applied in the form of 12 h infusion and irradiation can produce remissions in 50% of inoperable esophageal cancer cases, i.e., a rate of remission which is similar to that achieved by irradiation and bleomycin applied in the form of rapid (push) i.v. injections.

Adenocarcinoma↗
PubMed1980

Iron, copper, and zinc liver tissue levels in patients with malignant lymphomas.

Levels of iron, copper, and zinc in liver tissue and of copper in serum were studied in 53 cases of untreated malignant lymphoma (14 cases of Hodgkin's disease and 17 of lymphocytic and 22 of histiocytic lymphoma). The values were compared with the levels of these metals in the liver tissue of 23 healthy persons. Liver tissue was obtained by means of percutaneous biopsy examination with a Menghini needle. Part of the samples was used for histologic examination, and the remainder for metal level determination. Atomic absorption spectrophotometry was used in determining metal levels in dry liver tissue and in sera. In all malignant lymphoma patients, a significantly higher serum copper level was established (P < 0.05). A lower iron level in liver tissue was only found in those patients with lymphocytic lymphomas without a lymphomatous process in the liver (P < 0.05), while lymphomatous hepatic infiltration was associated with a higher iron level and lower copper level (P < 9.05). Significant changes in liver zinc levels were only proved by higher levels of this metal in patients with histiocytic lymphoma and lymphomatous hepatic infiltration (P < 0.05). The only redistribution of copper between the serum and liver tissue was found in those patients with lymphocytic lymphomas and lymphomatous hepatic infiltration.

Copper↗
PubMed1980

Combination of bleomycin and adriamycin with and without radiation on the treatment of inoperable esophageal cancer. A randomized study.

In a prospective randomized study, 31 patients with inoperable esophageal cancer were treated with a combination of bleomycin and adriamycin, and with a combination of these cytostatics and radiation. Evaluation of treatment results showed 3 partial remissions and 2 stable-disease cases in the group of 16 patients treated by cytostatic drugs alone; in all other cases, the disease progressed. The response rate achieved in this group was 19%. In the group including 15 patients who were irradiated with a dose of 3600--4000 rad and received simultaneously the same cytostatics with a somewhat lower dose of adriamycin, there were 3 complete remissions, 6 partial remissions, and 4 stable-disease cases, while in 2 cases the disease progressed. The response rate was 60%, which was statistically significant (P less than 0.025) when compared with the results achieved by the group receiving the bleomycin adriamycin combination. The average duration of remissions in the complete-response cases was 11 months, and in the partial-response cases, 5.2 months with combined treatment, and 4.2 months with combination chemotherapy. The toxic side-effects were tolerable for the patients, albeit more intensive with the combined-treatment modality. Four esophagobronchial fistulas (four disease progressions) and one rupture of the aorta were noted during treatment. This study has shown the advantages of chemoradiotherapeutic treatment of inoperable esophageal cancer.

Alopecia↗
PubMed1980

Treatment of metastatic brain tumors with the combination of 1-methyl-1-nitrosourea (MNU) and cyclophosphamide.

The combination of MNU and cyclophosphamide was applied in 29 consecutive previously untreated patients with metastatic brain tumors. An objective regression of the metastatic process in the brain, with seven complete and seven partial remission, was observed in 14 out of 29 patients (48%). In three patients the disease was stable, and in 12 it progressed in spite of treatment. The objective parameters used in monitoring the effect of therapy included brain scintiscan, computerized brain tomography and neurological clinical status. Median remission duration was 11.2 months in complete responders, and 5.6 months in partial responders. Median survival was also the longest in complete responders (15.7 months). The median survival of non-responding patients was only 3.1 months.

Adult↗
PubMed1980

Characteristics of respondents and non-respondents to a mailed questionnaire.

In establishing a cohort of U.S. nurses, an assessment of response bias was made comparing respondents and non-respondents with regard to age, education, state of residence, employment status, field of employment, and major specialty. Overall, the 122,328 respondents (69.7 per cent) and 43,222 non-respondents were quite similar. Together with the reasonable response rate in a homogeneous population, this suggests that estimation of exposure-disease associations is unlikely to be affected by major bias due to non-response.

Adult↗